NASHVILLE, Tenn.--(BUSINESS WIRE)--ObjectiveHealth, a Nashville-based integrated research and technology platform company, today announced a clinical research partnership with Urology of St. Louis.
NRX-101 is a fixed-dose, oral combination of D-cycloserine, an N-methyl-D-aspartate receptor modulator and broad spectrum antibiotic, and lurasidone, a D2/5-HT2a receptor antagonist.
Dr. Wallis is a Clinical Professor of Surgery in the Division of Urology at the University of Utah and Chief of Pediatric Urology at Primary Children’s Hospital. He is a board certified pediatric ...
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of April. The chart below provides highlights of key monograph updates made ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results